Chronix Biomedical Announces Multiple Poster Presentations at ASCO 2013

Data Highlight Next-Generation Sequencing of Cell-Free DNA to Detect Minimal Residual Disease in a Variety of Cancers

Chronix Biomedical Announces Multiple Poster Presentations at ASCO 2013

[email protected]

, a developer of blood-based molecular diagnostics, announces that four research abstracts highlighting the Company’s cell-free DNA technology for real-time cancer detection will be presented at the American Society of Clinical Oncology Annual Meeting 2013 (ASCO 2013) being held May 31 through June 4, 2013 at the McCormick Place Convention Center in Chicago. The abstracts highlight studies performed together with the MD Anderson Cancer Center in Houston, the Institute of Veterinary Medicine in Göttingen, Germany and the University of Toronto.

In addition to viewing the posters, ASCO 2013 attendees can meet the Chronix Biomedical management team and learn more about the Company’s diagnostic tests and clinical research plans by visiting Exhibit Booth #2074 or attending the Company’s cocktail reception Sunday evening, June 2 (see contact information below for details).

“The data presented in these four posters demonstrate the unique nature of our cancer biomarkers and their potential utility in a clinical setting,” said Howard B. Urnovitz, Ph.D., Chief Executive Officer of Chronix Biomedical. “We are excited to have such a strong presence at one of the world’s foremost oncology conferences, and look forward to discussing our development plans with physicians and industry leaders, including a multi-center neoadjuvant study with MD Anderson.”

Poster presenters will be available, and posters will be available for viewing. The posters highlighting Chronix Biomedical’s technology include:

Chronix Biomedical is a molecular diagnostics company developing blood tests primarily for cancer, including companion diagnostics and tests for detecting minimal residual disease. Chronix is scaling up to offer its pioneering tests through its own laboratories under CLIA certification in North America and the CE mark in Europe. The Company’s initial product is a test to be used by cancer treatment centers and oncologists in the treatment of breast cancer patients.

Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany and Brookings, South Dakota. It was the first team to use next-generation sequencing on cell-free DNA. The Company has two issued patents on the detection of cell-free DNA and RNA, and four patents pending using next-generation sequencing technology for the detection of breast cancer, prostate cancer and colorectal cancer – all of which can be done without the need for a tumor sample. For additional information please visit

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

The result, which beats the 35% reported by KRAS rival Amgen, sets Mirati up to file for FDA approval of the drug in the second half of next year.

Scorpion is working on precision oncology 2.0, including making better drugs for known targets, hitting undruggable targets and discovering new ones.